DevicePMAs@therightstef:P120021_S000 JSONTXT

{"project":"PMA_MER","denotations":[{"id":"T1","span":{"begin":0,"end":8},"obj":"http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C25425"},{"id":"T2","span":{"begin":46,"end":52},"obj":"http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C62103"},{"id":"T3","span":{"begin":97,"end":104},"obj":"http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C25366"},{"id":"T4","span":{"begin":110,"end":130},"obj":"http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C34619"},{"id":"T5","span":{"begin":151,"end":155},"obj":"http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C17102"},{"id":"T6","span":{"begin":159,"end":168},"obj":"http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14173"},{"id":"T7","span":{"begin":283,"end":286},"obj":"http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C45263"},{"id":"T8","span":{"begin":292,"end":300},"obj":"http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142832"},{"id":"T9","span":{"begin":342,"end":353},"obj":"http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C17721"},{"id":"T10","span":{"begin":358,"end":370},"obj":"http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125951"},{"id":"T11","span":{"begin":384,"end":394},"obj":"http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C25214"},{"id":"T12","span":{"begin":406,"end":411},"obj":"http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C80137"}],"text":"Approval for the AMPLATZER PFO Occluder. The device is indicated for percutaneous transcatheter closure of a patent foramen ovale (PFO) to reduce the risk of recurrent ischemic stroke in patients, predominantly between the ages of 18 and 60 years, who have had a cryptogenic stroke due to a presumed paradoxical embolism, as determined by a neurologist and cardiologist following an evaluation to exclude known causes of ischemic stroke."}

{"project":"PMA_Manual","denotations":[{"id":"T1","span":{"begin":0,"end":40},"obj":"pma_main"},{"id":"T2","span":{"begin":42,"end":52},"obj":"device_main"},{"id":"T3","span":{"begin":70,"end":136},"obj":"indication_main"},{"id":"T4","span":{"begin":137,"end":196},"obj":"indication_context"},{"id":"T6","span":{"begin":249,"end":321},"obj":"indication_context"},{"id":"T7","span":{"begin":323,"end":418},"obj":"indication_context"},{"id":"T8","span":{"begin":198,"end":247},"obj":"indication_context"}],"text":"Approval for the AMPLATZER PFO Occluder. The device is indicated for percutaneous transcatheter closure of a patent foramen ovale (PFO) to reduce the risk of recurrent ischemic stroke in patients, predominantly between the ages of 18 and 60 years, who have had a cryptogenic stroke due to a presumed paradoxical embolism, as determined by a neurologist and cardiologist following an evaluation to exclude known causes of ischemic stroke."}

{"project":"consensus_PMA_Age_Indications","denotations":[{"id":"T1","span":{"begin":232,"end":247},"obj":"age_range"},{"id":"T2","span":{"begin":232,"end":234},"obj":"age_start"},{"id":"T3","span":{"begin":239,"end":241},"obj":"age_end"},{"id":"T4","span":{"begin":242,"end":247},"obj":"age_end_unit"}],"text":"Approval for the AMPLATZER PFO Occluder. The device is indicated for percutaneous transcatheter closure of a patent foramen ovale (PFO) to reduce the risk of recurrent ischemic stroke in patients, predominantly between the ages of 18 and 60 years, who have had a cryptogenic stroke due to a presumed paradoxical embolism, as determined by a neurologist and cardiologist following an evaluation to exclude known causes of ischemic stroke."}

{"project":"Age_blah","denotations":[{"id":"T1","span":{"begin":232,"end":234},"obj":"age_start"},{"id":"T2","span":{"begin":239,"end":241},"obj":"age_end"},{"id":"T3","span":{"begin":242,"end":247},"obj":"age_end_unit"},{"id":"T4","span":{"begin":232,"end":241},"obj":"age_range"}],"text":"Approval for the AMPLATZER PFO Occluder. The device is indicated for percutaneous transcatheter closure of a patent foramen ovale (PFO) to reduce the risk of recurrent ischemic stroke in patients, predominantly between the ages of 18 and 60 years, who have had a cryptogenic stroke due to a presumed paradoxical embolism, as determined by a neurologist and cardiologist following an evaluation to exclude known causes of ischemic stroke."}

{"project":"Age_blah","denotations":[{"id":"T1","span":{"begin":232,"end":234},"obj":"age_start"},{"id":"T2","span":{"begin":239,"end":241},"obj":"age_end"},{"id":"T3","span":{"begin":242,"end":247},"obj":"age_end_unit"},{"id":"T4","span":{"begin":232,"end":241},"obj":"age_range"}],"text":"Approval for the AMPLATZER PFO Occluder. The device is indicated for percutaneous transcatheter closure of a patent foramen ovale (PFO) to reduce the risk of recurrent ischemic stroke in patients, predominantly between the ages of 18 and 60 years, who have had a cryptogenic stroke due to a presumed paradoxical embolism, as determined by a neurologist and cardiologist following an evaluation to exclude known causes of ischemic stroke."}

{"project":"PMA_age_indications","denotations":[{"id":"T2","span":{"begin":232,"end":234},"obj":"age_start"},{"id":"T1","span":{"begin":232,"end":247},"obj":"age_range"},{"id":"T3","span":{"begin":239,"end":241},"obj":"age_end"},{"id":"T4","span":{"begin":242,"end":247},"obj":"age_end_unit"}],"text":"Approval for the AMPLATZER PFO Occluder. The device is indicated for percutaneous transcatheter closure of a patent foramen ovale (PFO) to reduce the risk of recurrent ischemic stroke in patients, predominantly between the ages of 18 and 60 years, who have had a cryptogenic stroke due to a presumed paradoxical embolism, as determined by a neurologist and cardiologist following an evaluation to exclude known causes of ischemic stroke."}

{"project":"updated_tagging_age_PMA_annotations","denotations":[{"id":"T1","span":{"begin":232,"end":247},"obj":"age_range"},{"id":"T2","span":{"begin":232,"end":234},"obj":"age_start"},{"id":"T3","span":{"begin":239,"end":241},"obj":"age_end"},{"id":"T4","span":{"begin":242,"end":247},"obj":"age_end_unit"}],"text":"Approval for the AMPLATZER PFO Occluder. The device is indicated for percutaneous transcatheter closure of a patent foramen ovale (PFO) to reduce the risk of recurrent ischemic stroke in patients, predominantly between the ages of 18 and 60 years, who have had a cryptogenic stroke due to a presumed paradoxical embolism, as determined by a neurologist and cardiologist following an evaluation to exclude known causes of ischemic stroke."}